



Enablence

Technologies Inc.

**Annual General and Special Meeting
of Shareholders**

December 7, 2022

Disclaimer and Forward Looking Information Disclosure

This corporate presentation (the "Presentation") is being furnished on a confidential basis in order to provide readers certain information with respect to the business and operations of Enablece Technologies Inc. ("Enablece" or the "Company") current as of December 6, 2022, unless otherwise stated. The information in this Presentation is provided in summary form and does not purport to be complete. Each reader, by accepting delivery of this document, agrees not to make a photocopy or other copy or to divulge the contents hereof to any person other than a legal, business, investment, or tax advisor in connection with obtaining the advice of such person in respect of the Company.

Recipients of this Presentation who are considering acquiring securities of the Company are reminded that any such purchase or subscription must not be made solely on the basis of the information contained in this Presentation but are referred to the entire body of publicly disclosed information regarding the Company and the entirety of any agreements, term sheets and other disclosure which is provided in connection with any such acquisition of securities, and any other information being furnished to the investor. This Presentation is not intended to be, nor should it be, relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial condition or needs of any particular investor. These should be considered, with or without professional advice, when deciding if an investment is appropriate.

The Company does not guarantee the accuracy or completeness of such information. Statements in this Presentation are made as of the date of this Presentation unless stated otherwise, and neither the delivery of this Presentation at any time, nor any sale hereunder, shall under any circumstances create an implication that the information contained herein is correct as of any subsequent date.

Neither the issue of this Presentation nor any part of its contents is to be taken as any form of contract, commitment or recommendation on the part of the Company or the directors of the Company to proceed with any transaction or accept any offer and the right is reserved to terminate any discussions or negotiations with any prospective investors. The Company reserves the right without any notice or liability to the recipient of this Presentation or its advisers to: (i) change any of the procedures, timetable or requirements or terminate negotiations at any time prior to the signing of any binding agreement with investors; (ii) provide different information or access to information to different persons; and (iii) to negotiate at the same time with more than one person.

The securities of the Company described herein have not been and will not be registered under any United States federal or state securities law and may not be offered and sold in the United States, except that securities may be offered and sold to an investor that is an "accredited investor" as defined in Regulation D of Securities Act of 1933, as amended, of the United States of America. Prospective investors will be required to represent, among other things, that they qualify as "accredited investors" and are familiar with and understand the terms of the offering and have all requisite authority to make such investment. The securities will not be and have not been registered under the U.S. Securities Act or the securities laws of any state of the United States, and if sold in the United States will be "restricted securities" within the meaning of Rule 144 under the U.S. Securities Act. The securities may be resold, pledged or otherwise transferred only pursuant to an effective registration statement under the U.S. Securities Act or pursuant to an applicable exemption from the registration requirements of the U.S. Securities Act

Note: All financial figures contained in this presentation are in US dollars unless otherwise stated.




Meeting Agenda

- Call to order and appointment of Chairperson, Secretary, and Scrutineer
- Notice of Meeting, Quorum and Scrutineer's report
- Presentation of Financial Statements
- Matters to be acted upon:
 1. *Approval of Amended and Restated Equity Incentive Plan*
 2. *Appointment of Auditors*
 3. *Election of Directors*
- Conclusion of the Meeting of the Shareholders
- Management Presentation (CEO – Todd Haugen)
- Questions from Shareholders

At a Glance

- Share price – \$1.24 (as of Dec 6/22); 52 wk high/low - \$2.40/0.79
- Shares Issued and Outstanding – 18.5 million (22.3 million)
- Market Cap - \$20.5 million (as of Dec.5/22)
- Enterprise Value - \$20.3 million
- Offices – Ottawa (Head Office); Fremont (Head Office); Suzhou (Sales Office)

- TTM Sales – US\$ 2.0 million



Fiscal 2022 in Review




Q2 Completed Recapitalization Transaction – positions the Company's balance sheet for future growth



Amendment and restatement of senior secured loan – lowers interest rate and reduces cashflow burden



3 consecutive quarters of sales growth



Going Forward

Build Datacoms Business to Profitability Fy24Q2/3

- More than doubled Datacoms active Evaluations from \$1.9m-\$4.75m annual sales
- Expanded Customer Base (II-VI, SiPhx, Onet, ColorChip)

Release New Datacoms Products

- 5 DWDM's (50-100gig)
- 8 Channel CWDM

Increase Advanced Vision Investment

- Sales and Marketing
- Focused R&D
- Grow Capacity

Advanced Vision Definition

What is Advanced Vision?


- Controlled (coherent) light source
- Broader spectrum (eye safe)

Why is it Better?

- Velocity, position, direction, density, particle detection, gas detection, dimensions, ...
- Transparency variation

Where is it used?

- **Mobility** Automotive, Robotics, Drones, Marine
- **Medical** Ophthalmology, Dermatology, Otolaryngology
- **Manufacturing** contamination, maintenance, quality



TOF=>Time Of Flight, SWIR=>Short Wave InfraRed
FMCW=>Frequency Modulation Continuous Wave

Advanced Vision Market



24% vs 15% CAGR



FY26 40% vs 15% Margin




Higher Conversion Rate



Barriers to entry \$100m + 5-7 years

- \$80m capital
- 24-36 months process development
- \$2m knowledge acquisition



Sources: YOLÉ; Technavio; Expert Market Research

Advanced Vision Benefits

	Silicon Nitride (SiN)	Silicon Photonics	PLC
Efficiency	~	∅	✓
Sensitivity	~	∅	✓
Capacity	~	∅	✓
Yield	~	∅	✓
Miniaturization	~	✓	∅
Integration	✓	✓	~



Advanced Vision Strategy



Engage Market

[New Web Site](#)

RDK/PDK

Conferences/Trade shows

Academic Partnerships



Expand Capabilities

New product tech

New development tech

10x Capacity by FY26



Build Supply Chain

Certification Process

Primary/Secondary/Tertiary

Annual pricing concessions



Grow Skill and People

Automotive Sales Experience

Additional Designers

Additional Process Engineers

Technician 6 Sigma training

Advanced Vision Progress




FY22: 80% DATACOMS;
20% ADVANCED VISION



MORE THAN \$60M/YEAR
ACTIVE ADVANCED VISION
EVALUATIONS



ADVANCED VISION
EXCEEDS DATACOMS
REVENUE FY25



FY26: 30% DATACOMS;
70% ADVANCED VISION



The Enablence Advantage

- Experienced management team
- World class PLC and AI/ML technology
- Established track record of optical chip design and manufacturing
- Robust sales pipeline
- Total addressable market in excess of US \$80 billion by 2030

Q&A
